Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2015

01-12-2015 | Radiation Oncology

Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes

Authors: Dezheng Huo, MD, PhD, Ningqi Hou, PhD, Nora Jaskowiak, MD, FACS, David J. Winchester, MD, FACS, David P. Winchester, MD, FACS, Katharine Yao, MD, FACS

Published in: Annals of Surgical Oncology | Issue 13/2015

Login to get access

Abstract

Background

The effectiveness of postmastectomy radiotherapy (PMRT) in terms of survival for breast cancer patients with American Joint Committee on Cancer (AJCC) pT1–2 and one to three tumor positive lymph nodes is controversial, especially in this era of more effective systemic treatment.

Methods

Using data from the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program between 1998 and 2008, this study respectively identified 93,793 and 36,299 women with AJCC pT1-2pN1 breast cancer who underwent mastectomy. The association of PMRT use with overall and cause-specific survival was examined using multivariable Cox models in subgroups defined by tumor stage.

Results

In the NCDB cohort, 21.5 % of the patients (n = 20,236) received PMRT, and a very similar percentage (21.9 %, n = 7939) received PMRT in the SEER cohort. In the NCDB cohort, PMRT was associated with a 14 % relative risk reduction in all-cause mortality among the patients with two positive lymph nodes and tumors 2–5 cm in size or three positive nodes [hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.81–0.91; p < 0.0001], but PMRT had no beneficial effect for the patients with one positive node or two positive nodes and tumors 2 cm in size or smaller. Analysis of the SEER cohort confirmed this heterogeneous effect, showing PMRT to be associated with a 14 % relative risk reduction in breast cancer cause-specific mortality among the patients with two positive nodes and tumors 2–5 cm in size or three positive nodes (HR 0.86; 95 % CI 0.77–0.96; p = 0.007) but not in the other subgroup.

Conclusion

The effectiveness of radiotherapy depends on the combination comprising the number of positive lymph nodes and tumor size, which may enable more precise patient selection for PMRT.
Literature
1.
Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.PubMed
2.
Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst. 2001;93:979–89.CrossRefPubMed
3.
Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–990.CrossRefPubMed
4.
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network, 2011.
5.
Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.CrossRefPubMed
6.
Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.CrossRefPubMed
7.
Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.CrossRefPubMed
8.
Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.PubMed
9.
Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817–27.PubMed
10.
Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.CrossRefPubMed
11.
Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.CrossRefPubMed
12.
Recht A, Edge SB. Evidence-based indications for postmastectomy irradiation. Surg Clin North Am. 2003;83:995–1013.CrossRefPubMed
13.
Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–53.CrossRefPubMed
14.
Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRef
15.
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCentralCrossRefPubMed
16.
Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) Research Data (1973–2009), based on the November 2011 submission: National Cancer Institute, Bethesda, MD, DCCPS, Surveillance Research Program, Surveillance Systems Branch, 2012.
17.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRefPubMed
18.
Cox D. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187–220.
19.
Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24:4901–7.CrossRefPubMed
20.
Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1–2 node-positive breast cancer. J Clin Oncol. 2005;23:1409–19.CrossRefPubMed
21.
Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with t1–t2 and 1–3 positive lymph nodes: a meta-analysis. PLoS One. 2013;8:e81765.PubMedCentralCrossRefPubMed
22.
Kunkler IH, Canney P, van Tienhoven G, Russell NS, Group MESTM. Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol R Coll Radiol. 2008;20:31–4.CrossRefPubMed
23.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRefPubMed
24.
Moo TA, McMillan R, Lee M, et al. Selection criteria for postmastectomy radiotherapy in t1–t2 tumors with 1 to 3 positive lymph nodes. Ann Surg Oncol. 2013;20:3169–74.CrossRefPubMed
25.
Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012;83:e577–81.CrossRefPubMed
26.
McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1–2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392–8.CrossRefPubMed
27.
DaiKubicky C, Mongoue-Tchokote S. Prognostic significance of the number of positive lymph nodes in women with T1-2N1 breast cancer treated with mastectomy: should patients with 1, 2, and 3 positive lymph nodes be grouped together? Int J Radiat Oncol Biol Phys. 2013;85:1200–5.CrossRefPubMed
28.
Hardenbergh PH, Bentel GC, Prosnitz LR, Marks LB. Postmastectomy radiotherapy: toxicities and techniques to reduce them. Semin Radiat Oncol. 1999;9:259–68.CrossRefPubMed
29.
Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–24.PubMedCentralCrossRefPubMed
30.
Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.CrossRefPubMed
31.
Du X, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked medicare and SEER data. Surveillance, Epidemiology, and End Results. J Clin Epidemiol. 1999;52:463–70.CrossRefPubMed
32.
Walker GV, Giordano SH, Williams M, et al. Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registries. Int J Radiat Oncol Biol Phys. 2013;86:686–93.CrossRefPubMed
33.
Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012;118:333–41.PubMedCentralCrossRefPubMed
34.
Dragun AE, Huang B, Gupta S, Crew JB, Tucker TC. One decade later: trends and disparities in the application of post-mastectomy radiotherapy since the release of the American Society of Clinical Oncology clinical practice guidelines. Int J Radiat Oncol Biol Phys. 2012;83:e591–6.CrossRefPubMed
35.
Metadata
Title
Use of Postmastectomy Radiotherapy and Survival Rates for Breast Cancer Patients with T1–T2 and One to Three Positive Lymph Nodes
Authors
Dezheng Huo, MD, PhD
Ningqi Hou, PhD
Nora Jaskowiak, MD, FACS
David J. Winchester, MD, FACS
David P. Winchester, MD, FACS
Katharine Yao, MD, FACS
Publication date
01-12-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 13/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4528-x

Other articles of this Issue 13/2015

Annals of Surgical Oncology 13/2015 Go to the issue

Endocrine Tumors

The Effect of Thyroiditis on the Yield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer

Hepatobiliary Tumors

Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection

Gynecologic Oncology

Improving Sentinel Lymph Node Detection in Patients with Cervical Cancer

Gynecologic Oncology

A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection

Breast Oncology

Positive Margins After Oncoplastic Surgery for Breast Cancer

Head and Neck Oncology

A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database